Viravaxx closes Series A investment round

Viravaxx AG, an emerging biopharmaceutical company focused on the development of antiviral vaccines for difficult to treat virus infections as well as diagnostic products for the detailed analysis of the immunological response to virus infections, announced today the closing of private financing round in the amount of €4.22 million.

Participating in the financing were a group of private investors and Viravaxx’s parent company Biomay AG.

The capital raised in this round will be employed for advancing Viravaxx’s lead product, the hepatitis B vaccine VVX001 into a clinical proof of concept study, as well as completing the design of innovative vaccines for human rhinovirus (HRV), human immunodeficiency virus (HIV) and respiratory syncytial virus (RSV). In addition, a diagnostic multiplexed peptide array designed for analysis of the IgG response to HRV infection will be prepared for marketing to the research market.

Rainer Henning, CEO of Viravaxx commented: “We are very grateful for the commitment of our new investors, who recognized the potential of our approach. We now have the resources available to demonstrate the clinical feasibility of our lead product VVX001. We have received already significant interest from prominent researchers in the respiratory field in our prospective HRV diagnostic tool. We look forward to make it available to them in the near future.”

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)